Lu Song Selected Research

Benserazide

1/2020	Systemic Inflammation Increases the Susceptibility to Levodopa-Induced Dyskinesia in 6-OHDA Lesioned Rats by Targeting the NR2B-Medicated PKC/MEK/ERK Pathway.
1/2018	The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.
1/2017	Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease.
12/2014	Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
1/2012	Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
8/2010	Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lu Song Research Topics

Disease

22	Parkinson Disease (Parkinson's Disease) 01/2022 - 06/2009
14	Dyskinesias (Dyskinesia) 01/2022 - 08/2010
9	Neoplasms (Cancer) 07/2022 - 05/2016
6	Neuroinflammatory Diseases 01/2022 - 01/2018
5	Crohn Disease (Crohn's Disease) 01/2021 - 01/2013
3	COVID-19 01/2021 - 12/2020
3	Inflammation (Inflammations) 01/2020 - 09/2019
3	Osteosarcoma (Osteogenic Sarcoma) 10/2019 - 03/2013
2	Sepsis (Septicemia) 07/2022 - 01/2021
2	Acute Lung Injury 07/2022 - 09/2019
2	Infections 01/2021 - 02/2013
2	Acute Kidney Injury (Acute Renal Failure) 01/2021 - 01/2021
2	Stroke (Strokes) 01/2020 - 02/2017
2	Bone Resorption 06/2019 - 01/2019
2	Diabetes Mellitus 01/2017 - 01/2017
2	Neoplasm Metastasis (Metastasis) 05/2016 - 03/2013
2	Ulcerative Colitis 02/2014 - 01/2013
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 02/2014 - 01/2013
1	Autistic Disorder (Autism) 01/2022
1	Multiple System Atrophy 01/2022
1	Chronic Renal Insufficiency 01/2022
1	Autism Spectrum Disorder 01/2022
1	Down Syndrome (Down's Syndrome) 01/2022
1	Movement Disorders (Movement Disorder) 01/2022
1	Adrenoleukodystrophy (Adrenoleukodystrophy, X-Linked) 09/2021
1	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/2021
1	Diabetes Complications 01/2021
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2021
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2021
1	Insulin Resistance 01/2021
1	Pulmonary Embolism 01/2021
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2021
1	Hemorrhagic Stroke 01/2021
1	Fever (Fevers) 12/2020
1	Chronic Disease (Chronic Diseases) 12/2020
1	Circulating Neoplastic Cells 11/2019

Drug/Important Bio-Agent (IBA)

17	Levodopa (L Dopa)FDA LinkGeneric 01/2022 - 06/2009
6	BenserazideIBA 01/2020 - 08/2010
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2013
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2021
4	LipopolysaccharidesIBA 01/2021 - 09/2019
4	Dopamine (Intropin)FDA LinkGeneric 01/2017 - 03/2010
4	Pharmaceutical PreparationsIBA 01/2014 - 08/2010
3	Caspase 3 (Caspase-3)IBA 01/2021 - 03/2013
3	Messenger RNA (mRNA)IBA 06/2019 - 01/2013
3	Neuroprotective AgentsIBA 05/2016 - 03/2010
3	G-protein-coupled receptor kinase 6IBA 01/2013 - 09/2012
2	CytokinesIBA 01/2022 - 01/2018
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 11/2019
2	MicroRNAs (MicroRNA)IBA 01/2021 - 09/2013
2	Circular RNAIBA 01/2021 - 01/2021
2	Interleukin-17 (Interleukin 17)IBA 01/2021 - 06/2019
2	Nucleic AcidsIBA 12/2020 - 12/2020
2	Oxidopamine (6 Hydroxydopamine)IBA 01/2020 - 03/2010
2	LigandsIBA 11/2019 - 01/2014
2	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 01/2018 - 01/2018
2	Chemokine ReceptorsIBA 05/2016 - 01/2014
2	AntibodiesIBA 05/2016 - 08/2013
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2016 - 08/2013
2	N-Methylaspartate (NMDA)IBA 08/2013 - 08/2009
2	Apomorphine FDA Link 01/2013 - 03/2010
1	Long Noncoding RNAIBA 07/2022
1	pyruvate dehydrogenase kinase 4IBA 07/2022
1	Cell Adhesion MoleculesIBA 01/2022
1	Biological ProductsIBA 01/2022
1	SynucleinsIBA 01/2022
1	CreatinineIBA 01/2022
1	(+)-JQ1 compoundIBA 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 09/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	Nerve Growth Factor Receptor (Nerve Growth Factor Receptor, Low Affinity)IBA 01/2021
1	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2021
1	Vacuolar Proton-Translocating ATPases (V-Type ATPase)IBA 01/2021
1	AerosolsIBA 01/2021
1	Troponin IIBA 01/2021
1	TroponinIBA 01/2021
1	Trinitrotoluene (TNT)IBA 01/2021
1	AnticoagulantsIBA 01/2021
1	Growth Differentiation Factor 15IBA 01/2021
1	ras Guanine Nucleotide Exchange FactorsIBA 01/2021
1	fibrin fragment D (D-dimer)IBA 01/2021
1	Fibrinogen (Factor I)FDA Link 12/2020
1	Indicators and Reagents (Reagents)IBA 12/2020
1	Ubiquitin-Specific ProteasesIBA 10/2020
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2020
1	Adenosine Triphosphate (ATP)IBA 01/2020
1	Clodronic Acid (Clodronate)IBA 01/2020
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020
1	MucinsIBA 01/2020
1	Immunoglobulins (Immunoglobulin)IBA 01/2020
1	Liposomes (Liposome)IBA 01/2020
1	HydrogelsIBA 01/2020
1	Epithelial Cell Adhesion MoleculeIBA 11/2019
1	indirubin-3'-monoximeIBA 10/2019

Therapy/Procedure

9	Therapeutics 01/2021 - 01/2012
4	Microspheres (Microsphere) 01/2017 - 08/2010
2	Intraperitoneal Injections 01/2017 - 01/2013
1	Walkers 01/2022
1	Immunotherapy 01/2021